Medicare AdvantageCoverageMedium impact
MA08.075i, Ramucirumab (Cyramza®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Aug 18, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.075i for Ramucirumab (Cyramza®) has been updated with changes to medical necessity criteria, medical coding requirements, and general guidelines. This affects billing and coverage determination for this oncology drug used primarily in cancer treatment.
Action Required
By August 18, 2025: Billing team and oncology providers must review updated medical necessity criteria for Ramucirumab (Cyramza®) at the source URL. Update prior authorization documentation requirements and coding guidelines in billing system. Verify medical necessity documentation meets new criteria before submitting claims to avoid denials.